GLUCOPHAGE XR Drug Patent Profile

Which patents cover Glucophage Xr, and when can generic versions of Glucophage Xr launch?

Glucophage Xr is a drug marketed by Emd Serono Inc and is included in one NDA.

The generic ingredient in GLUCOPHAGE XR is metformin hydrochloride. There is one drug master file entry for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glucophage Xr

A generic version of GLUCOPHAGE XR was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for GLUCOPHAGE XR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	352
Patent Applications:	38
Drug Prices:	Drug price information for GLUCOPHAGE XR
DailyMed Link:	GLUCOPHAGE XR at DailyMed

See drug prices for GLUCOPHAGE XR

Recent Clinical Trials for GLUCOPHAGE XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China National Center for Cardiovascular Diseases	PHASE4
James Wang	Phase 1
United States Department of Defense	Phase 1

See all GLUCOPHAGE XR clinical trials

US Patents and Regulatory Information for GLUCOPHAGE XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003		DISCN	Yes	No

Expired US Patents for GLUCOPHAGE XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000

International Patents for GLUCOPHAGE XR

See the table below for patents covering GLUCOPHAGE XR around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1224	Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
Australia	3182899
Australia	736951
Brazil	9908911
Canada	2320900	SYSTEME D'APPORT A LIBERATION LENTE BIPHASIQUE DESTINE A DESMEDICAMENTS A SOLUBILITE ELEVEE ET PROCEDE ASSOCIE (BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD)
China	1203846
China	1295467

Supplementary Protection Certificates for GLUCOPHAGE XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0861666	07C0006	France		PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID
1412357	PA2008013	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
1412357	PA2008013,C1412357	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
1412357	SPC/GB08/040	United Kingdom		PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
1412357	C300357	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716

Glucophage XR (metformin ER) market dynamics and financial trajectory: pricing, demand drivers, exclusivity, and competitive risk

Last updated: June 24, 2026

Executive summary: Glucophage XR is an extended-release (ER) metformin product that competes in a generic-dominated diabetes market. Market dynamics are driven by (1) persistent prevalence of type 2 diabetes and guideline-based metformin first-line use, (2) ongoing payer pressure toward lowest net cost (including A-rated generics and authorized generics where available), and (3) substitution intensity between metformin ER products (strength-by-strength interchangeability). Financial trajectory is shaped less by patent exclusivity than by competitive pricing, channel mix, and contracting. As a legacy, off-patent brand, Glucophage XR’s revenue path has largely tracked generic erosion and retail-to-wholesale reimbursement shifts rather than incremental innovation.

---

What is Glucophage XR and how is it positioned in type 2 diabetes treatment?

Glucophage XR is the extended-release formulation of metformin hydrochloride used to improve glycemic control in type 2 diabetes. Clinically, metformin ER is used for first-line therapy in many guidelines and as add-on therapy when targets are not met. In practice, dosing and tolerability (GI side effects) influence selection between immediate-release and ER.

Why extended-release metformin wins prescriptions despite generic penetration

• ER formulations reduce peak-trough fluctuations and can improve tolerability versus immediate-release metformin for some patients.
• Prescriber and plan behavior typically favors:
  • ER versus IR when a patient has GI intolerance.
  • Any covered ER option that is lowest net cost and easy to adjudicate.
• Even with generic availability, branded products can hold share in pockets with:
  • formulary carve-outs,
  • step-therapy complexities,
  • patient-specific tolerance history,
  • prescriber familiarity.

Key market implication

The product’s “defensibility” is primarily contracting and formulary position, not IP exclusivity.

---

How do market dynamics shape Glucophage XR demand and net sales trends?

1) Diabetes prevalence and persistence drive baseline demand

The metformin class benefits from long treatment duration in chronic disease. Demand is less cyclical than many specialty categories, but it is still sensitive to:

• diagnosis rates,
• adherence and persistence,
• payer tightening,
• competition within the metformin ER shelf.

2) Payer pressure favors lowest net cost metformin ER

In most geographies and channels, metformin is heavily substituted. Net sales for any brand are constrained by:

• generic price compression,
• increased use of “any metformin ER” formulary language,
• lower copays for preferred generics.

3) Contracting and channel mix matter more than incremental innovation

Typical drivers of revenue trajectory:

• Pharmacy benefit manager (PBM) formulary placement.
• Rebate structures and market-share protection strategies by brand manufacturers.
• Shifts between:
  • retail,
  • mail,
  • long-term care and institutional channels.

4) Substitution intensity within ER products

Because metformin ER products are therapeutically equivalent, substitution is frequent at the point of dispensing. This compresses:

• brand realized prices,
• brand-to-generic share.

---

How does competition from generic metformin ER affect pricing and share for Glucophage XR?

Competitive set and substitution risk

Glucophage XR competes against a broad field of:

• generic metformin ER tablets (multiple strengths),
• authorized generics (where applicable),
• alternative ER metformin branded and unbranded options.

Risk pattern for brands: revenue generally declines as plan formularies migrate toward the lowest-cost option and as pharmacy dispensing systems substitute.

Strength-by-strength economics

Metformin ER is marketed across multiple dosage strengths. Competitive intensity varies by strength due to:

• number of approved ANDAs,
• manufacturing capacity dispersion,
• local contracting,
• short-term supply and pricing swings.

Channel sensitivity

Institutional formularies and long-term care pharmacies often standardize to a narrow list of preferred generics, reinforcing brand erosion.

---

What is the patent and exclusivity landscape for Glucophage XR?

Glucophage XR is metformin ER. The market reality is that metformin’s core chemistry is long off-patent, and the dominant protection (when any remains) typically relates to specific formulations, particle engineering, or manufacturing methods. For Glucophage XR specifically, market participants typically treat it as commercially dependent on branding and contracting rather than active exclusivity.

How exclusivity affects the financial trajectory

For legacy metformin ER brands:

• Any remaining narrow formulation or process patents have limited ability to stop generic entry across the broad product landscape.
• Financial outcomes therefore track generic penetration and payer-driven switching.

---

When do Glucophage XR brand exclusivity and patent barriers end, and what does that mean for launch risk?

Launch risk profile

Generic entry risk is structurally high because:

• metformin ER has extensive generic availability,
• regulatory barriers are not comparable to biologics or novel small-molecule IP-protected assets,
• substitution is straightforward for therapeutically equivalent products.

Bottom line: The “timing” variable for financial trajectory is less about a single expiration date and more about:

• ongoing generic price convergence,
• repeated formulary tendering,
• rebate resets.

---

How do FDA regulatory status and Orange Book listings affect Glucophage XR competition?

Orange Book relevance (commercial utility)

For legacy metformin products:

• Orange Book listings can show whether any listed patents remain on specific dosage forms.
• In practice, even with some listed patents, market access is usually dominated by generic approvals and formulary behavior, unless patents are enforced via litigation.

Practical outcome

For investors and competitors, Orange Book is primarily a map of:

• which SKUs might be constrained,
• whether Paragraph IV challenges or settlements exist for specific strengths.

---

What generic entry risks exist for Glucophage XR in the US?

US generic entry dynamics

Generic risk for metformin ER brands typically manifests through:

• broad ANDA availability across strengths,
• automatic substitution rules and PBM formulary breadth,
• incremental erosion rather than a single step-function event.

Financial translation

• Revenue tends to show gradual decline driven by share loss.
• Price realization drops as the brand becomes non-preferred or loses rebate economics.

---

What patent litigation and settlements historically impact metformin ER brands?

Litigation-driven scenarios

For most metformin ER brands, litigation is not the dominant economic variable in the long run. Where litigation occurred in past cycles, the economic impacts were typically:

• temporary SKU-level protection,
• settlement-driven generic launch timing,
• post-settlement share stabilization followed by renewed erosion.

In current market framing, Glucophage XR’s key exposure is contracting and competitive shelf dynamics rather than active enforcement.

---

How does Glucophage XR compare with competing metformin ER products on commercial positioning?

Comparison dimensions that drive market outcomes

• Formulary preference and rebate value
• Patient adherence and tolerability narratives (ER positioning)
• Copay tiers (particularly under Medicare Part D and Medicaid managed care)
• PBM contracting outcomes

Competitive outcome

Brands with similar ER dosing and labeling typically lose share when PBMs standardize on a preferred generic set.

---

What does the financial trajectory likely look like: revenue, pricing, and profitability direction?

Observed pattern in mature genericized chronic-care markets

For metformin ER brands like Glucophage XR, typical financial trajectory features:

• declining revenue due to generic substitution,
• price erosion from net realizations,
• margin pressure if rebates increase to maintain shelf presence,
• volatility from contracting cycles.

Most likely direction of realized net pricing

• Retail and mail pharmacy net prices generally compress over time.
• Even if list prices remain high, net revenue declines due to rebates and competitive discounts.

Profitability constraint

Brand manufacturers often face:

• rising spend to defend share,
• limited ability to differentiate clinically beyond ER tolerability framing.

---

Revenue exposure: which factors most influence Glucophage XR financial performance?

1) Formulary status and placement

• preferred vs non-preferred tier
• preferred PA criteria presence
• step therapy and substitution policy impacts

2) PBM contracting cadence

• annual and semiannual formulary resets
• tendering and market-share protection bids

3) Mix shift between ER products and IR where plans encourage simplification

Even if ER is preferred for tolerability, plans may route to preferred low-cost alternatives, including IR in certain cohorts.

4) Inventory and supply stability

Metformin ER is supply-chain sensitive. Constraints can temporarily increase brand share, but such impacts typically reverse quickly absent sustained exclusivity.

---

What commercial opportunities remain for Glucophage XR despite generic erosion?

Where brands can still earn share

• Patient-specific continuity when switching is clinically sensitive.
• Local formulary exceptions and clinician-led prescribing patterns.
• Non-medical switching deterrence where copays remain manageable.

What is usually limited

• Long-term share expansion.
• Pricing power.
• Protection from repeated generic tendering.

---

Key Takeaways

• Glucophage XR’s market dynamics are dominated by generic metformin ER substitution, not patent-led exclusivity.
• Demand is durable due to chronic type 2 diabetes treatment, but brand revenues trend downward as payer contracting shifts to lowest net cost options.
• Financial trajectory is most sensitive to PBM formulary position, rebate economics, and strength-by-strength competitive intensity.
• Generic entry risk is continuous and typically produces incremental share erosion rather than single-event disruption.

---

FAQs

1) Is Glucophage XR still a competitive product versus generic metformin ER?

It can retain share where formulary placement and patient-specific tolerance support continued use, but US competition is structurally biased toward generics on net cost.

2) What drives switching from branded Glucophage XR to generic metformin ER?

PBM formulary tiering, rebate competition, and pharmacy substitution rules are the primary drivers.

3) Does metformin ER have differentiation advantages that protect brand revenue?

Differentiation is limited. ER tolerability can influence selection, but therapeutically equivalent generic ER options cap brand pricing and share.

4) Are there formulation or manufacturing patents that materially change Glucophage XR’s risk profile?

Any remaining protection, if present, is typically narrow versus the broad availability of generic metformin ER, so overall commercial risk remains dominated by contracting.

5) How do Medicare Part D and Medicaid managed care affect Glucophage XR pricing trajectory?

They amplify payer-driven selection, typically accelerating net pricing compression as preferred generics expand.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. American Diabetes Association. Standards of Care in Diabetes. https://diabetesjournals.org/care/issue
3. Centers for Medicare & Medicaid Services. Medicare Part D Drug Pricing and Rebate Program resources. https://www.cms.gov/